Form 4: LivaNova CFO Alex Shvartsburg Reports Stock Transactions

CFO of LivaNova PLC, Alex Shvartsburg, reports acquisition and disposal of ordinary shares, restricted stock units (RSUs), performance stock units (PSUs), and stock appreciation rights (SARs) on March 30, 2024.

Summary

• On March 30, 2024, Alex Shvartsburg, CFO of LivaNova PLC, reported transactions involving the company's ordinary shares, restricted stock units (RSUs), performance stock units (PSUs), and stock appreciation rights (SARs).
• Shvartsburg acquired 14,752 ordinary shares through the vesting of RSUs and PSUs.
• He disposed of 6,310 ordinary shares to cover tax liabilities at a price of $55.94 per share.
• He also acquired various RSUs and PSUs granted under the LivaNova PLC 2015 and 2022 Incentive Award Plans.
• These grants are subject to vesting schedules and performance conditions related to cumulative adjusted free cash flow (FCF), total shareholder return (TSR), and return on investment capital (ROIC).
• Additionally, he acquired 15,631 stock appreciation rights (SARs) that vest over four years.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, with a mix of vesting and new grants. The sentiment is neutral to slightly positive, as it indicates alignment of management interests with shareholder value.

Positives

• The vesting of RSUs and PSUs indicates that performance targets were met, leading to the release of shares to the CFO.
• The grant of new RSUs, PSUs, and SARs aligns the CFO's interests with the long-term performance of the company.

Negatives

• The disposal of shares to cover tax liabilities, while a normal occurrence, reduces the CFO's direct holdings in the company.

Risks

• Future vesting of RSUs and PSUs is contingent on continued service and the achievement of performance targets related to TSR, ROIC, and FCF.
• Forfeiture of unvested RSUs, PSUs, and SARs is possible if the CFO leaves the company before the vesting dates.

Future Outlook

Future vesting of RSUs, PSUs, and SARs is contingent on continued service and the achievement of performance targets related to TSR, ROIC, and FCF over specified periods.

Industry Context

Executive compensation through equity grants is a common practice in publicly traded companies to align management's interests with those of shareholders. The specific metrics used (TSR, ROIC, FCF) reflect the company's strategic priorities.

Comparison to Industry Standards

• Equity compensation packages for CFOs in publicly traded companies typically include a mix of stock options, restricted stock units (RSUs), and performance-based stock units (PSUs).
• The vesting schedules and performance metrics used by LivaNova (TSR, ROIC, FCF) are common in the healthcare industry.
• Comparable companies such as Medtronic, Boston Scientific, and Abbott also utilize similar equity compensation structures to incentivize their executives.

Stakeholder Impact

• Shareholders: The equity grants align management's interests with shareholder value creation.
• Employees: The equity grants can serve as a motivation for employees, as they see management's compensation tied to company performance.

Next Steps

• Continued monitoring of performance against TSR, ROIC, and FCF targets to determine future vesting of PSUs.
• Tracking of vesting schedules for RSUs and SARs.

Key Dates